

REMARKS

After entry of the present Amendment, claims 1, 4, 10-14, 17, 19-28 are pending in the application.

Claims 10, 11, 14, 19, and 24-28 have been amended. Specifically, in claims 10 and 24, "acylamido" has been replaced with "acylamino," as suggested by the Examiner, and as supported in the specification at least at page 15, lines 15-27. The terms "sulfonamido" and "ureido" have been added to claims 10 and 24 to provide antecedent basis to claims depending therefrom. The sulfonamido feature is supported by the original claims and in the specification at least at page 18, line 34. The ureido feature is supported by the original claims and in the specification at least at page 19, line 2. Claims 11, 19 and 25 were amended to clarify the language identifying the claimed substituent groups. Claim 14 is amended to correspond to claims pending in other jurisdictions. Claims 26-28 were amended to replace the "Pr" group with the structural designation of an n-propyl group, as intended by applicants and as would clearly be understood by the skilled artisan. Applicants respectfully assert that no new matter has been introduced by way of the amendments to the claims.

The claims stand variously rejected. Each of the rejections is traversed as discussed below.

Rejections Under 35 USC § 112, second paragraph

In the Office Action, claims 10, 11, 18, 19, 24 and 25-28 are rejected as being indefinite. The Office Action states: 1) the "acylamido" substituent in the claims should be "acylamino"; 2) the terms "ureido" and "sulfonamido" in claims 11, 19 and 25 do not find antecedent basis in the claims from which they depend; and 3) the term "Pr" is not described in the specification. Applicants respectfully traverse the rejections, but have amended the claims as described below in order to advance prosecution.

"Acylamido" has been replaced with "acylamino" in the amended claims, as suggested by the Examiner.

Claims 10, 14, and 25 have been amended to provide antecedent basis for the terms "ureido" and "sulfonamido" in dependent claims 11, 19 and 25.

"Pr" has been replaced with the appropriate chemical structure for a normal propyl group. Applicants note that a Pr group is depicted in Figure 8, compound 686. One of skill in the art would readily understand that Applicants intended this group to represent an n-propyl group, as is now shown in the claims.

In view of the above, Applicants respectfully request notification from the examiner that the rejections under 35 U.S.C. § 112, second paragraph have been withdrawn.

Non-statutory obviousness-type double patenting


Claims 1-4, 10, 12-18 and 20-24 are rejected under the judicially-created doctrine of obviousness-type double patenting as being unpatentable over claims 1-19 of copending Application No. 10/426,147.

Applicants respectfully request that the rejection be held in abeyance until such time that one or both of the applications issue and the rejection is no longer provisional.

CONCLUSION

In view of the foregoing, reconsideration and allowance of claims 1, 4, 10-14, 17, 19-28 is respectfully requested. The Examiner is invited to contact the undersigned by telephone at the Examiner's convenience should any issues remain with respect to the Application.

Respectfully submitted,



Wendy M. Seffrood
Reg. No. 52,205

DATE: August 2, 2005

Docket No.: 065435-9009 US01
Michael Best and Friedrich LLP
One South Pinckney Street
P.O. Box 1806
Madison, WI 53701-1806
(608) 257-3501